Pharmacogenomic and Pharmacometabolomic Biomarkers of the Efficacy and Safety of Antidepressants: Focus on Selective Serotonin Reuptake Inhibitors

被引：0
作者：
A. E. Gareeva [1 ]
L. S. Borodina [2 ]
S. A. Pozdnyakov [3 ]
I. F. Timerbulatov [4 ]
机构：
[1] Institute of Biochemistry and Genetics, Ufa Federal Research Center, Russian Academy of Sciences, Ufa
[2] Kemerovo State University, Kemerovo
[3] Russian Medical Academy of Continuous Professional Education, Russian Ministry of Health, Moscow
[4] Republican Narcology Dispenser No. 1, Ministry of Health of the Republic of Bashkortostan, Ufa
[5] Moscow Scientific and Applied Narcology Center, Moscow City Health Department, Moscow
[6] Usoltsev Central Clinical Psychiatric Hospital, Moscow
[7] Russian Medical University, Russian Ministry of Health, Moscow
来源：
Neuroscience and Behavioral Physiology | 2024年 / 54卷 / 8期
关键词：
antidepressants; pharmacogenomics; pharmacometabolomics; selective serotonin reuptake inhibitors;
D O I：
10.1007/s11055-024-01716-5
中图分类号：
学科分类号：
摘要：
The efficacy and safety of psychopharmacotherapy with antidepressants is of great medical importance. The search for clinical and biological predictors for the selection of optimal psychopharmacotherapy with antidepressants is under active investigation throughout the world. Most studies address the search for associations between polymorphic variants of genes and the efficacy and safety of therapy. However, data on patients’ genetic polymorphisms are often insufficient for predicting the efficacy and safety of a drug. Contemporary research on the personalization of pharmacotherapy should include not only genetic, but also phenotypic biomarkers. This is important because genotyping, for example, cannot accurately predict the real metabolic activity of an isoenzyme. Successful treatment of depression remains a complex task; between-individual differences in responses to antidepressants are common. About half of patients with depressive disorders do not respond to the first attempt at antidepressant therapy. Serious side effects in pharmacotherapy with antidepressants and discontinuation of treatment due to intolerance are associated with lack of therapeutic efficacy. This review presents results from the latest studies of “omics” biomarkers of the efficacy and safety of antidepressants. © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2024.
引用
收藏
页码：1205 / 1214
页数：9
相关论文
共 86 条
  • [21] Kao C.F., Kuo P.H., Yu Y.W., Et al., Gene-based association analysis suggests association of HTR2A with antidepressant treatment response in depressed patients, Front. Pharmacol, 11, (2020)
  • [22] Oz M.D., Baskak B., Uckun Z., Et al., Association between serotonin 2A receptor (HTR2A), and serotonin transporter (SLC6A4) and brain-derived neurotrophic factor (BDNF) gene polymorphisms and citalopram/sertraline induced sexual dysfunction in MDD patients, Pharmacogenomics, J, 20, 3, pp. 443-450, (2020)
  • [23] Wan Y.S., Zhai X.J., Tan H.A., Et al., Associations between the 1438A/G, 102T/C, and rs7997012G/A polymorphisms of HTR2A and the safety and efficacy of antidepressants in depression: a meta-analysis, Pharmacogenomics, J, 21, 2, pp. 200-215, (2021)
  • [24] Secher A., Bukh J., Bock C., Et al., Antidepressive-drug-induced bodyweight gain is associated with polymorphisms in genes coding for COMT and TPH1, Int. Clin. Psychopharmacol, 24, 4, pp. 199-203, (2009)
  • [25] Yohn C.N., Shifman S., Garino A., Et al., Fluoxetine effects on behavior and adult hippocampal neurogenesis in female C57BL/6J mice across the estrous cycle, Psychopharmacology (Berlin), 237, 5, pp. 1281-1290, (2020)
  • [26] Ochi T., Vyalova N.M., Losenkov I.S., Et al., Limited associations between 5-HT receptor gene polymorphisms and treatment response in antidepressant treatment-free patients with depression, Front. Pharmacol, 10, (2019)
  • [27] Scutt G., Overall A., Scott R., Et al., Does the 5-HT1A rs6295 polymorphism influence the safety and efficacy of citalopram therapy in the oldest old?, Ther. Adv. Drug Saf, 9, 7, pp. 355-366, (2018)
  • [28] Villafuerte S.M., Vallabhaneni K., Sliwerska E., Et al., SSRI response in depression may be influenced by SNPs in HTR1B and HTR1A, Psychiatr. Genet, 19, 6, pp. 281-291, (2009)
  • [29] Kato M., Fukuda T., Wakeno M., Et al., Effect of 5-HT1A gene polymorphisms on antidepressant response in major depressive disorder”, Am, J. Med. Genet. B Neuropsychiatr. Genet, 150B, 1, pp. 115-123, (2009)
  • [30] Pain O., Hodgson K., Trubetskoy V., Et al., Identifying the common genetic basis of antidepressant response, Biol. Psychiatry Glob. Open Sci, 2, 2, pp. 115-126, (2022)
123456789